PMID- 31844618
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 2214-031X (Print)
IS  - 2214-0328 (Electronic)
IS  - 2214-031X (Linking)
VI  - 19
DP  - 2019 Oct
TI  - Sargassum integerrimum inhibits oestrogen deficiency and hyperlipidaemia-induced 
      bone loss by upregulating nuclear factor (erythroid-derived 2)-like 2 in female 
      rats.
PG  - 106-117
LID - 10.1016/j.jot.2019.03.002 [doi]
AB  - ETHNOPHARMACOLOGICAL RELEVANCE: Oestrogen deficiency, high incidences of 
      hyperlipidaemia (HLP) and accelerated bone loss frequently occur in 
      postmenopausal women. There is an urgent need to develop functional foods or 
      specific drugs to protect against bone loss induced by oestrogen deficiency with 
      HLP. AIM OF THE STUDY: In this study, we investigated the potential inhibitory 
      effects of Sargassum integerrimum (SI) on bone loss in an ovariectomized rat 
      model with HLP. MATERIALS AND METHODS: The rats were treated for 12 weeks, and 
      then, bone mineral density, bone biomechanical, bone microstructure, bone 
      morphology, biomarkers of HLP oxidative stress and side effects were determined. 
      Immunohistochemical staining and Western blot were performed to evaluate related 
      protein expression. RESULTS: The femur bone mineral density increased (P < 0.05), 
      and the microscopic structures (ratio of bone volume to total volume [BV/TV], 
      connectivity density [Conn.D], trabecular number [Tb.N] and trabecular thickness 
      [Tb.Th]) of the bone trabecula and mechanical properties (maximum and breaking 
      load [ML and BL, respectively]) improved after SI treatment (P < 0.05). 
      Furthermore, the levels of HLP biomarkers (total cholesterol, triglyceride and 
      low-density lipoprotein) were significantly decreased (P < 0.05), whereas the 
      levels of antioxidant markers (superoxide dismutase and total antioxidant 
      capacity) were increased (P < 0.05). Similar results were obtained with 
      immunohistochemical staining, whereas the Western blot assay showed that SI 
      stimulated the expression of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
      in bone. CONCLUSION: Our data indicate that rats exposed to SI treatment for 12 
      weeks did not exhibit noticeable side effects. In conclusion, SI suppressed bone 
      loss induced by ovariectomized and the associated HLP in rats by activating Nrf2, 
      which could be a promising treatment option for osteoporosis induced by oestrogen 
      deficiency and HLP in postmenopausal women. TRANSLATIONAL SCOPE STATEMENT: Our 
      study verified that SI prevented bone loss in rats with oestrogen deficiency with 
      HLP by upregulating nuclear factor (erythroid-derived 2)-like 2. Furthermore, no 
      side effect was observed after the long-term administration of SI. Those results 
      suggested SI could be developed as a functional food or drug for postmenopausal 
      osteoporosis induced by oestrogen deficiency with HLP.
CI  - (c) 2019 Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking 
      Orthopaedic Society.
FAU - Wu, Kefeng
AU  - Wu K
AD  - Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong 
      Medical University, Zhanjiang, Guangdong, 524023, China.
FAU - Gong, Zhongqin
AU  - Gong Z
AD  - Shenzhen Ritzcon Biological Technology Co., Ltd., Shenzhen, 518000, China.
FAU - Zou, Liyi
AU  - Zou L
AD  - Department of Pharmacology, Guangdong Medical University, Dongguan, 523808, 
      Guangdong, China.
FAU - Ye, Hua
AU  - Ye H
AD  - Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong 
      Medical University, Zhanjiang, Guangdong, 524023, China.
FAU - Wang, Changxiu
AU  - Wang C
AD  - School of Public Health, Guangdong Medical University, Dongguan, Guangdong, 
      523808, China.
FAU - Liu, Yangchun
AU  - Liu Y
AD  - Jiangxi Medical College, Queen Mary College of Nanchang University, Nanchang, 
      Jiangxi, 330000, China.
FAU - Liang, Yan
AU  - Liang Y
AD  - Department of Pharmacology, Guangdong Medical University, Zhanjiang, Guangdong, 
      524023, China.
FAU - Li, Yanping
AU  - Li Y
AD  - Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong 
      Medical University, Zhanjiang, Guangdong, 524023, China.
FAU - Ren, Jianwei
AU  - Ren J
AD  - School of Biomedical Sciences, The Chinese University of Hong Kong, New 
      Territories, Hong Kong, China.
FAU - Cui, Liao
AU  - Cui L
AD  - Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong 
      Medical University, Zhanjiang, Guangdong, 524023, China.
AD  - Department of Pharmacology, Guangdong Medical University, Zhanjiang, Guangdong, 
      524023, China.
FAU - Liu, Yi
AU  - Liu Y
AD  - Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong 
      Medical University, Zhanjiang, Guangdong, 524023, China.
LA  - eng
PT  - Journal Article
DEP - 20190327
PL  - Singapore
TA  - J Orthop Translat
JT  - Journal of orthopaedic translation
JID - 101625127
PMC - PMC6896726
OTO - NOTNLM
OT  - Bone loss
OT  - HLP, hyperlipidaemia
OT  - Hyperlipidaemia
OT  - Nrf2
OT  - OS, oxidative stress
OT  - Oestrogen deficiency
OT  - Oxidative stress
OT  - SOD, superoxide dismutase
OT  - Sargassum integerrimum
OT  - TOAC, total antioxidant capacity
EDAT- 2019/12/18 06:00
MHDA- 2019/12/18 06:01
PMCR- 2019/03/27
CRDT- 2019/12/18 06:00
PHST- 2018/11/27 00:00 [received]
PHST- 2019/02/17 00:00 [revised]
PHST- 2019/03/04 00:00 [accepted]
PHST- 2019/12/18 06:00 [entrez]
PHST- 2019/12/18 06:00 [pubmed]
PHST- 2019/12/18 06:01 [medline]
PHST- 2019/03/27 00:00 [pmc-release]
AID - S2214-031X(18)30175-X [pii]
AID - 10.1016/j.jot.2019.03.002 [doi]
PST - epublish
SO  - J Orthop Translat. 2019 Mar 27;19:106-117. doi: 10.1016/j.jot.2019.03.002. 
      eCollection 2019 Oct.